MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel recessive mutations in MSTO1 cause cerebellar atrophy with pigmentary retinopathy.
|
29339779 |
2018 |
MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia.
|
28544275 |
2017 |
MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia.
|
28544275 |
2017 |
MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
MSTO1 is a cytoplasmic pro-mitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans.
|
28554942 |
2017 |
MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia.
|
28544275 |
2017 |
MYOPATHY, MITOCHONDRIAL, AND ATAXIA
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Retinitis Pigmentosa
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
As of late, MSTO1 mutations have been reported to cause clinical manifestations such as myopathy, cerebellar atrophy and ataxia, motor developmental delay, and pigmentary retinopathy.
|
30684668 |
2020 |
Retinitis Pigmentosa
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
While the full genotype-phenotype spectrum remains to be explored, pathogenic variants in MSTO1 have recently been reported in a small number of patients presenting with a phenotype of cerebellar ataxia, congenital muscle involvement with histologic findings ranging from myopathic to dystrophic and pigmentary retinopathy.
|
31463572 |
2019 |
Retinitis Pigmentosa
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Novel recessive mutations in MSTO1 cause cerebellar atrophy with pigmentary retinopathy.
|
29339779 |
2018 |
Retinitis Pigmentosa
|
0.130 |
Biomarker
|
disease |
HPO |
|
|
|
Cerebellar atrophy
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Bi-allelic loss-of-function variants in MSTO1 manifest clinically with a remarkably consistent phenotype of childhood-onset muscular dystrophy, corticospinal tract dysfunction and early-onset non-progressive cerebellar atrophy.
|
31463572 |
2019 |
Cerebellar atrophy
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Recently, MSTO1 mutations have been shown to cause clinical manifestations suggestive of mitochondrial dysfunction, such as muscle weakness, short stature, motor developmental delay, and cerebellar atrophy.
|
29339779 |
2018 |
Cerebellar atrophy
|
0.120 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Muscle Weakness
|
0.110 |
GeneticVariation
|
phenotype |
BEFREE |
Recently, MSTO1 mutations have been shown to cause clinical manifestations suggestive of mitochondrial dysfunction, such as muscle weakness, short stature, motor developmental delay, and cerebellar atrophy.
|
29339779 |
2018 |
Muscle Weakness
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
Anxiety
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Depressive disorder
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dwarfism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital pectus excavatum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hyperthyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypesthesia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Language Disorders
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
Lipoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Micrognathism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Mild Mental Retardation
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|